Treatment of central serous chorioretinopathy with beta-blocker metipranolol.

IF 0.7

Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia Pub Date : 2015-03-01 Epub Date: 2013-03-21 DOI:10.5507/bp.2013.015

Oldrich Chrapek, Barbora Jirkova, Vit Kandrnal, Jiri Rehak, Martin Sin

{"title":"Treatment of central serous chorioretinopathy with beta-blocker metipranolol.","authors":"Oldrich Chrapek, Barbora Jirkova, Vit Kandrnal, Jiri Rehak, Martin Sin","doi":"10.5507/bp.2013.015","DOIUrl":null,"url":null,"abstract":"Aim: The purpose of this study was to evaluate the effect of the systemically administered betablocker metipranolol on the course of central serous chorioretinopathy (CSC).Methods: A prospective double-blind study involving 48 patients with a first attack of CSC not exceeding two weeks and who agreed to the follow-up ophthalmology examinations every week. The group was divided into a metipranolol group (n=23), receiving 10 mg of drug twice per day and a placebo group (n=25). The outcome measure was time in weeks from drug intervention (metipranolol vs. placebo) to reattachment of macula neuroepithelium.Results: There was no statistically significant difference in duration of CSC in patients who used metipranolol and those who used placebo (P=0.341).Conclusions: In a prospective double-blind study, we found no effect of the betablocker metipranolol on the duration of central serous chorioretinopathy.","PeriodicalId":520569,"journal":{"name":"Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia","volume":" ","pages":"120-3"},"PeriodicalIF":0.7000,"publicationDate":"2015-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"16","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.5507/bp.2013.015","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2013/3/21 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 16

Abstract

Aim: The purpose of this study was to evaluate the effect of the systemically administered betablocker metipranolol on the course of central serous chorioretinopathy (CSC).

Methods: A prospective double-blind study involving 48 patients with a first attack of CSC not exceeding two weeks and who agreed to the follow-up ophthalmology examinations every week. The group was divided into a metipranolol group (n=23), receiving 10 mg of drug twice per day and a placebo group (n=25). The outcome measure was time in weeks from drug intervention (metipranolol vs. placebo) to reattachment of macula neuroepithelium.

Results: There was no statistically significant difference in duration of CSC in patients who used metipranolol and those who used placebo (P=0.341).

Conclusions: In a prospective double-blind study, we found no effect of the betablocker metipranolol on the duration of central serous chorioretinopathy.

查看原文本刊更多论文

受体阻滞剂美安洛尔治疗中枢性浆液性脉络膜视网膜病变。

目的:本研究的目的是评估全身给药β受体阻滞剂美安洛尔对中枢性浆液性脉络膜视网膜病变(CSC)病程的影响。方法:采用前瞻性双盲研究，纳入48例首次发作不超过两周的CSC患者，并同意每周随访眼科检查。将患者分为美地萘洛尔组(n=23)和安慰剂组(n=25)。美地萘洛尔组每日2次，每次10 mg。结果测量从药物干预(美安洛尔vs安慰剂)到黄斑神经上皮重新附着的时间(周)。结果:美萘洛尔组与安慰剂组CSC持续时间差异无统计学意义(P=0.341)。结论:在一项前瞻性双盲研究中，我们发现β受体阻滞剂美安洛尔对中枢性浆液性脉络膜视网膜病变持续时间没有影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia

自引率

0.00%

发文量